Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7619388 | 0.91 | CHRM1 (0.55) | CHRM1CHRM2CHRM3 | |
| SCHEMBL8404086 | 0.72 | CHRM1 (0.56) | CHRM1CHRM2CHRM3 | |
| SCHEMBL8402584 | 0.71 | CHRM2 (1.00) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL5139637 | 0.70 | CHRM2 (0.55) | CHRM1CHRM2CHRM3 | |
| SCHEMBL9422305 | 0.70 | CHRM2 (0.55) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL7613827 | 0.69 | CHRM1 (0.49) | CHRM1CHRM2CHRM3 | |
| SCHEMBL7611948 | 0.69 | CHRM1 (0.59) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL12951109 | 0.69 | CHRM2 (0.54) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL9342146 | 0.69 | CHRM1 (0.53) | CHRM1CHRM2CHRM3 | |
| SCHEMBL13592738 | 0.68 | CHRM2 (0.53) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | claimed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | claimed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | claimed |
| US-5712297-A | COGNITION ACTIVATORS; ALZHEIMER*S DISEASE | NOVO NORDISK A/S (DK) | 1998-01-27 | — | — | US | claimed |
| CN-1133008-A | Antipsychotic method | NOVO NORDISK AS (DK) | 1996-10-09 | — | — | CN | claimed |
| EP-0732925-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-09-25 | — | — | EP | claimed |
| WO-1995017185-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | claimed |
| EP-0384288-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1995-05-24 | — | — | EP | claimed |
| EP-0384288-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-08-29 | — | — | EP | claimed |
| EP-0709094-B1 | Tetrahydropyridine oxadiazole or thiadiazole compound for treating anxiety | LILLY CO ELI (US) | 2000-04-05 | — | — | EP | disclosed |
| US-5708014-A | SUBSTITUTED TETRAHYDROPYRIDINYL-1,2,5-OXADIAZOLES OR THIADIAZOLES | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1996013167-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0709094-A2 | Method for treating anxiety using a tetrahydropyridine oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |